FDA Not Saying What House Democrats Want To Hear
Executive Summary
Henry Waxman and House Democrats held an Oversight and Government Reform Committee meeting on GlaxoSmithKline's Avandia to highlight the need to stronger postmarketing oversight FDA.
You may also be interested in...
Avandia Advisory Cmte. Could Be Observational Data’s Coming Out Party
The recommendations from FDA's joint advisory committee review of a signal of potential cardiovascular risk for GlaxoSmithKline's type 2 diabetes therapy Avandia (rosiglitazone) will likely be determined by how much weight the panel gives to meta-analysis as a means of assessing a drug's safety
Avandia Advisory Cmte. Could Be Observational Data’s Coming Out Party
The recommendations from FDA's joint advisory committee review of a signal of potential cardiovascular risk for GlaxoSmithKline's type 2 diabetes therapy Avandia (rosiglitazone) will likely be determined by how much weight the panel gives to meta-analysis as a means of assessing a drug's safety
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa